louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06887868: Immediate Effect of Mobilization with Movement on Squat Self-reported Functional Ability, Pain Intensity, and Pain-free Range of Motion in People with Knee Osteoarthritis
Official title: Immediate Effect of Mobilization with Movement on Squat Self-reported Functional Ability, Pain Intensity, and Pain-free Range of Motion in People with Knee Osteoarthritis: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Knee Osteoarthritis (Knee OA)
Keywords: Knee Osteoarthritis
manual therapy
mobilization with movement
functional status
Mulligan concept
neurophysiological effect
Lead sponsor: Escola Superior de Tecnologia da Saúde do Porto
Sponsor class: OTHER
First posted: 2025-03-20
Enrollment: 40
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Mobilization with movement (MWM) appears to reduce pain, improve knee range of motion, and enhance physical functioning in individuals with knee osteoarthritis (KOA). However, it remains unclear whether the severity grading of structural damage in KOA affects its effects. This study aims to analyze the immediate effect of MWM on squat self-reported functional ability, pain intensity, and pain-free range of motion in people with KOA, and to verify it its effect is influenced by the severity grading of structural damage.


Eligibility criteria: Inclusion Criteria:

* male or female;
* aged over 45 years;
* clinically diagnosed with symptomatic unilateral KOA, classified as grade 1-3 according to the Kellgren and Lawrence system;
* fulfilled the classification criteria of the American College of Rheumatology for KOA;
* reported frequent episodes of pain in the knee joint during sit-to-stand movements for at least 3 months.

Exclusion Criteria:

* had KOA secondary to rheumatoid arthritis and other inflammatory and autoimmune conditions;
* reported lumbar pain radiating to the knee or lumbar pain as the primary complaint;
* had a history of knee or lower limb surgery;
* had a systemic or local infection;
* had received an intra-articular corticosteroid or hyaluronic acid injection within the past 6 months;
* reported current or past (within 4 weeks) oral corticosteroid use;
* had any condition in the lower limbs that would prevent performing the deep squat test;
* had clinical conditions in which manual therapy is generally contraindicated (such as fracture, osteoporosis, instability, infectious arthritis, tumors, joint ankylosis, acute inflammatory disorders, or lack of a diagnosed joint lesion).

Primary outcomes:
measure: Functional ability
timeFrame: Baseline
measure: Knee Pain
timeFrame: Baseline
measure: Pain free Range of Motion (ROM)
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Porto
country: Portugal
facility: E2S | P.PORTO - Escola Superior de Saúde do Politécnico do Porto
Study officials:
References:
Clinical trial NCT06990568: Impact of Probiotics on Antibiotic-associated Diarrhea in Community-acquired Pneumonia
Official title: The Effect of Probiotic Administration on the Incidence of Antibiotic-associated Diarrhea in Patients With Community-acquired Pneumonia
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Pneumonia
Probiotics
Diarrhea
Lead sponsor: National Health Insurance Service Ilsan Hospital
Sponsor class: OTHER
First posted: 2025-05-25
Enrollment: 100
Sex: ALL
Minimum age (years): 19
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study goal is to determine whether oral administration of a probiotic mixture can reduce the incidence of antibiotic-associated diarrhea in patients with community-acquired pneumonia.


Eligibility criteria: Inclusion Criteria:

* Adult patients aged 19 years or older admitted with a diagnosis of community-acquired pneumonia
* Patients eligible for oral medication administration (able to take oral or enteral feeding)

Exclusion Criteria:

* Sepsis patients
* Patients admitted to the intensive care unit (ICU) following endotracheal intubation
* Elderly patients aged 80 years or older
* Pregnant women
* Patients who have diarrhea at the time of admission
* Patients with a history of using probiotics within 3 months prior to admission
* Patients with a history of using laxatives within 1 week prior to admission
* Patients suspected of being in shock (mean arterial pressure \< 65 mmHg) at the time of admission

Primary outcomes:
measure: Occurrence of antibiotic-associated diarrhea
timeFrame: Within 14 days after the cessation of Lacidofil or placebo administration
Secondary outcomes:
measure: Occurrence of Clostridium difficile infection
timeFrame: Within 14 days after the cessation of Lacidofil or placebo administration
measure: Total length of hospitalization
timeFrame: Within 14 days after the cessation of Lacidofil or placebo administration
measure: Duration of antibiotic use
timeFrame: Within 14 days after the cessation of Lacidofil or placebo administration
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00533468: "Lidocaine 4% Cream (LMX4) vs Placebo for Pain Due to Lumbar Puncture in Infants 0-60 Days of Age."
Official title: "Lidocaine 4% Cream (LMX4) vs Placebo for Pain Due to Lumbar Puncture in Infants 0-60 Days of Age."
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain
Keywords: pain
lumbar puncture
neonates
infants
emergency department
topical anesthesia
LMX4
Lead sponsor: State University of New York at Buffalo
Sponsor class: OTHER
Collaborators: name: Ferndale Laboratories, Inc.
First posted: 2007-09-21
Enrollment: 70
Sex: ALL
Minimum age (years): 0
Maximum age (years): 60
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The study's hypothesis is LMX4 cream, a topical anesthetic cream, will reduce the pain of infants undergoing Lumbar Puncture (spinal tap).

Detailed description: Pain of infants will be measured using the Neonatal Facial Coding System by videotaping the infant's face while they undergo the procedure. A comparison between the group that received active drug and the group that received placebo will allow a measurement of the difference, if any, of the pain experienced during the procedure of the infants.

Eligibility criteria: Inclusion Criteria:

* Full term (\>=37 weeks gestation)
* Age 0-60 Days
* Undergoing Lumbar Puncture

Exclusion Criteria:

* Unstable
* Premature (\<37 weeks gestation)
* Allergy to study medicine
* Parent refusal of consent

Primary outcomes:
measure: Neonatal Facial Coding System Score
timeFrame: Score was measured at baseline, upon positioning for the procedure, immediately prior to needle insertion, during needle insertion, 1 minute post-needle insertion, and post-procedure when the infant had recovered from the procedure and was swaddled
Secondary outcomes:
measure: Time of Procedure
timeFrame: Infant's stay in the Emergency Department
measure: Percentage of Procedures With Success
timeFrame: During patient's Emergency Department Stay
Other outcomes:
Locations:
city: Buffalo
country: United States
facility: Women's and Children's Hospital of Buffalo
state: New York
Study officials:
affiliation: SUNY Buffalo
name: James L Reingold, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01297868: Impact of Exercise on Retinal Microvascular Regulation Measured by Dynamic Vessel Analysis in Healthy Individuals
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Middle-aged Subjects
Age Range Was 18 to 31 Years
Caucasian Whites
Males and Females
Lead sponsor: University Medicine Greifswald
Sponsor class: OTHER
First posted: 2011-02-17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthy middle-aged subjects, unselected volunteers

Brief summary: Objective The investigators assessed the acute impact of physical exercise on retinal vessel regulation. This might be of clinical importance if retinal vessel regulation is examined with the very sensitive method of the dynamic vessel analyzer Design Forty middle aged (age range 18 to 31 years, mean age 24 years) healthy subjects (26 female / 14 male) had retinal examinations with static and dynamic vessel analysis prior and after (0.5h, 1.5h, 2.5h) intense exercise of 20 minutes.


Eligibility criteria: Inclusion Criteria:

* healthy middle-aged subjects

Exclusion Criteria:

* volunteers with systemic or ocular diseases

Primary outcomes:
measure: retinal vessel diameter
Secondary outcomes:
Other outcomes:
Locations:
city: Greifswald
country: Germany
facility: University Eye Hospital
Study officials:
References:
Clinical trial NCT00164268: Ke Ala Lokahi Demonstration Project for Sexual and Domestic Violence Prevention
Official title: Ke Ala Lokahi Demonstration Project for the Early Intervention and Prevention of Sexual and Domestic Violence Among Racial and Ethnic Populations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Domestic Violence
Keywords: Intimate partner violence
Sexual violence
Cultural intervention
Native Hawaiian
Lead sponsor: Centers for Disease Control and Prevention
Sponsor class: FED
First posted: 2005-09-14
Enrollment: 300
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the project is to examine the efficacy of a culturally-based intervention, compared to standard agency services, in enhancing self-care among Native Hawaiian women and decreasing IPV/SV perpetration and related factors among Native Hawaiian men.

Detailed description: Turning Point for Families in Hilo, Hawaii is developing, implementing, and evaluating a culturally-based intervention using Native Hawaiian values, beliefs, and practices to address intimate partner and sexual violence among Native Hawaiian perpetrators and victims/survivors.

Eligibility criteria: Inclusion Criteria:

* Men and women self-identified as Native Hawaiian referred for agency services due to intimate partner or sexual violence

Exclusion Criteria:

* See above. No other exclusion criteria.

Primary outcomes:
measure: Subsequent incidents of intimate partner or sexual violence for up to 2 years post-intervention
Secondary outcomes:
measure: Attitudes, behaviors, and cultural identity assessed at 3-months, 6-months, and 15-months following treatment initiation
Other outcomes:
Locations:
city: Hilo
country: United States
facility: Turning Point for Families
state: Hawaii
Study officials:
affiliation: Turning Point for Families
name: Linda Slutter
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04653168: A Study of LY3041658 in Healthy Participants
Official title: A Single Dose, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Injections of LY3041658 in Healthy Participants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2020-12-04
Enrollment: 16
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The main purpose of this study is to evaluate the safety and tolerability of LY3041658 in healthy participants. The study will measure how the body absorbs, breaks down and gets rid of LY3041658.


Eligibility criteria: Inclusion Criteria:

* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and ECG.
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* Have Body mass index (BMI) within the range 18.5 - 35.0 kilograms per square meter (kg/m2) (inclusive).

Exclusion Criteria:

* Have a significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, immune, neurological, dermatological, or psychiatric disorder capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the Study intervention or interfering with the interpretation of data.
* Have self-perceived dullness or loss of sensation on either side of their abdomen.
* Have any condition that could affect pain perception from an injection.
* Have excessive tattoos or scars over the abdomen, or other factors (eg, rash, excessive folds of skin) that, in the investigator's opinion, would interfere with injection site assessments.

Primary outcomes:
measure: Number of Participants With incidence and severity of Injection Site Reaction (ISR)
timeFrame: Baseline up to Day 15
measure: Visual Analog Scale (VAS) Score for Injection Site Pain
timeFrame: Baseline up to Day 1
Secondary outcomes:
measure: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3041658
timeFrame: Predose up to day 85 postdose
measure: PK: Area Under the Concentration Versus Time Curve (AUC) from time 0 to infinity of LY3041658
timeFrame: Predose up to day 85 postdose
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Lilly Centre for Clinical Pharmacology
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT04172168: Left Ventricular Free-wall Ruptrue After Acute Myocardial Infarction (LVFR-AMI)
Official title: Clinical Characteristics of Left Ventricular Free-wall Ruptrue After Acute Myocardial Infarction
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Myocardial Infarction
Keywords: Left Ventricular Free-wall Ruptrue
Acute myocardial infarction
Coronary angiography
Lead sponsor: Xiamen Cardiovascular Hospital, Xiamen University
Sponsor class: OTHER
First posted: 2019-11-21
Enrollment: 17568
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population of acute myocardial infarction (STEMI or NSTEMI) patients.

Brief summary: The Left Ventricular Free-wall Ruptrue (LVFR) is a serious complication caused high mortality.

Detailed description: The actual mortality of LVFR is close to 100%. Despite the mortality rate for LVFR has been decreasing with the development of reperfusion therapy, the serious complication remains a difficult challenge. The coronary anatomy distribution associated with LVFR has an interesting phenomenon. From the perspective of different coronary distribution, we can better known the risk factors related to LVFR.

Eligibility criteria: Inclusion Criteria:

* Patients be admitted for acute myocardial infarction (STEMI or NSTEMI)

Exclusion Criteria:

* Non-cardiovascular comorbidity for AMI

Primary outcomes:
measure: Rate of heart ruputre
timeFrame: Mortality 30 days
Secondary outcomes:
measure: Rate of cardiogenic shock
timeFrame: Hospitalization 30 days
measure: Rate of cardiac arrest
timeFrame: Hospitalization 30 days
Other outcomes:
Locations:
city: Xiamen
country: China
facility: Xiamen Cardiovascular Hospital Xiamen University
state: Fujian
Study officials:
affiliation: Cardiovascular Hospital, Xiamen University
name: Yan Wang, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04281368: Analysis of All Stillbirths in Stockholm County 2017, a Multidisciplinary Audit
Official title: Analysis of All Stillbirths in Stockholm County 2017, a Multidisciplinary Audit
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intra-Uterine Death
Keywords: IUFD
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2020-02-24
Enrollment: 79
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All stillbirths in Stockholm 2017

Brief summary: All stillbirths in Stockholm during 2017 were analysed according to the primary outcomes which were preventable/non-preventable deaths and the level of delay. The secondary outcomes were: causes of death, standard of care pre and post stillbirth and if a summary of the possible causes of death was made as well as the planning of supervision of the next pregnancy.

Detailed description: This is a retrospective cohort study. A multidisciplinary team consisting of three obstetricians, one midwife and one neonatologist was assembled. The team represented the largest hospitals in the region-Karolinska University Hospital and Stockholm Soderl Hospital. Each team member in the audit group had access to all the medical patient charts from the hospitals and also the majority of the charts from the antenatal care clinics (ANC). Each team member independently assessed each case regarding causes of death, preventable/non-preventable deaths, the level of delay if there was any and the standard of healthcare provided to the patients with stillbirth, the postmortem examination of infant and mother and if there were any recommendations given for the next pregnancy. Multiple meetings were organized for discussing the results of the individual assessment of each case. To enable an ethical discussion every member of the audit group signed a confidentiality form and all cases were assessed by comparison with local guidelines in praxis.

Eligibility criteria: Inclusion Criteria:

* All stillbirths in Stockholm 2017

Exclusion Criteria:

* Missed abortion

Primary outcomes:
measure: The rate of preventable/non-preventable deaths and the level of delay
timeFrame: 2017
Secondary outcomes:
measure: The frequency of different causes of death
timeFrame: 2017
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Eva Wiberg-Itzel
Study officials:
affiliation: KI
name: Eva Wiberg-Itzel, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sterpu I, Bolk J, Perers Oberg S, Hulthen Varli I, Wiberg Itzel E. Could a multidisciplinary regional audit identify avoidable factors and delays that contribute to stillbirths? A retrospective cohort study. BMC Pregnancy Childbirth. 2020 Nov 16;20(1):700. doi: 10.1186/s12884-020-03402-z.
Clinical trial NCT00136968: Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy
Official title: Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Fungal Infection
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
Collaborators: name: Mclean Hospital
First posted: 2005-08-29
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: The purpose of this study is to determine the amount of voriconazole in the brain by fluorine-magnetic resonance spectroscopy (MRS) and to compare brain levels to plasma levels.


Eligibility criteria: Inclusion Criteria:

* Healthy male volunteers 18-55 years of age

Exclusion Criteria:

* Subjects with any condition affecting drug absorption
* Subjects with a positive urine drug screen

Primary outcomes:
measure: Assess brain levels of voriconazole in the brain using a non-evasive technique of MRS
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00525668: Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
Official title: Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Relapsing-remitting Multiple Sclerosis
Keywords: multiple sclerosis
inflammation
neurodegeneration
neuroprotection
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2007-09-06
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypothesis:

Sunphenon, a green tea extract containing 95% egcg, given daily as oral medication over a period of 18 months has anti-inflammatory and neuroprotective properties in patients with relapsing-remitting multiple sclerosis as assessed by magnetic resonance imaging and clinical examination (EDSS and MSFC).

Detailed description: This multicentric, national study investigates the efficacy and safety of EGCG in patients with relapsing-remitting multiple sclerosis.

Eligibility criteria: Inclusion Criteria:

* male and female subjects age 18 to 60
* relapsing-remitting course of MS
* stable treatment with glatiramer acetate at least 6 months prior to inclusion

Exclusion Criteria:

* primary or secondary progressive forms of MS
* clinically relevant heart, lung, liver, kidney diseases
* regular hepatotoxic co-medication
* drug addiction
* alcohol abuse

Primary outcomes:
measure: number of new T2 lesions on brain MRI performed after 18 months of Sunphenon treatment compared to baseline MRI in the verum arm versus placebo
timeFrame: 18 months
Secondary outcomes:
measure: development of brain atrophy under treatment with EGCG vs. placebo
timeFrame: 18 months
measure: Safety and tolerability
timeFrame: 18 months
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: NeuroCure Clinical Research Center, Charite University, Berlin
city: Berlin
country: Germany
facility: Outpatient Clinic for Neuroimmunology at the ECRC, Charite University, Berlin
Study officials:
affiliation: Experimental and Clinical Research Center, Charite University, Berlin, Germany
name: Judith Bellmann-Strobl, Dr., MD
role: PRINCIPAL_INVESTIGATOR
affiliation: NeuroCure Clinical Research Center, Charité University, Berlin, Germany
name: Friedemann Paul, Prof., MD
role: STUDY_DIRECTOR
References:
citation: Bellmann-Strobl J, Paul F, Wuerfel J, Dorr J, Infante-Duarte C, Heidrich E, Kortgen B, Brandt A, Pfuller C, Radbruch H, Rust R, Siffrin V, Aktas O, Heesen C, Faiss J, Hoffmann F, Lorenz M, Zimmermann B, Groppa S, Wernecke KD, Zipp F. Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial. Neurol Neuroimmunol Neuroinflamm. 2021 Mar 24;8(3):e981. doi: 10.1212/NXI.0000000000000981. Print 2021 May.